CD4+ T Cells Predict Relapse in Pemphigus Vulgaris Treated With Rituximab: A Retrospective Study
Oral Diseases · 2026
DOI: 10.1111/odi.70234 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, 2026. Verfasst von Simone Liguori und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy. Hauptthemen laut MEDLINE: Pemphigus, Rituximab, CD4-Positive T-Lymphocytes, Immunologic Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
This study evaluated the CD4 + T‐cell role in mediating post‐Rituximab Pemphigus vulgaris (PV) relapse, comparing CD4 + count and CD4 + /CD20 + ratio between patients who achieved remission and those who relapsed.
Methods
The clinical course of 27 PV patients treated with Rituximab was evaluated after a 32‐month median follow‐up. CD4 + and CD20 + counts and CD4 + /CD20 + ratio were longitudinally collected at treatment start date (T0), at 2‐month intervals after Rituximab, until B‐cell repopulation, at B‐cell repopulation, at 6‐, 12‐, and 24‐month intervals after repopulation, and at the end of follow‐up or at relapse.
Results
Patients were administered Rituximab as adjuvant therapy: 16 (59%) relapsed while 11 (41%) achieved clinical remission. Higher CD4 + count ( p = 0.02*) and CD4 + /CD20 + ratio ( p = 0.004**) were found at B‐cell repopulation in patients experiencing remission. Moreover, a significant difference ( p = 0.002**) in post‐repopulation CD4 + T‐cell course was found between groups, with patients in clinical remission reporting a mean decrease of 233.5 cells/μL during follow‐up and relapsing patients experiencing a mean increase of 539.4 cells/μL and reaching the maximum CD4 + value at relapse.
Conclusions
Lower CD4 + T‐cell value at repopulation and increasing post‐repopulation CD4 + T‐cell count were predictive of disease relapse suggesting a time‐dependent role of CD4 + T cells in post‐Rituximab PV reactivation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy.
- Department of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy.
- Clinical and Experimental Cytometry Unit, Centre for Advanced Biotechnology Franco Salvatore, CEINGE, Naples, Italy.
ORCID-Profile: Simone Liguori, Noemi Coppola, Federica Canfora, Ilaria Mormile
Zitieren
APA
Liguori, S., Coppola, N., Ruoppo, E., Canfora, F., Mignogna, G., Mormile, I., Fiore, A., Castaldo, G., Mignogna, M. D., & Leuci, S. (2026). CD4+ T Cells Predict Relapse in Pemphigus Vulgaris Treated With Rituximab: A Retrospective Study. Oral Diseases. https://doi.org/10.1111/odi.70234
Vancouver
Liguori S, Coppola N, Ruoppo E, Canfora F, Mignogna G, Mormile I, et al. CD4+ T Cells Predict Relapse in Pemphigus Vulgaris Treated With Rituximab: A Retrospective Study. Oral Diseases. 2026. doi:10.1111/odi.70234
BibTeX
@article{Liguori2026,
author = {Liguori, Simone and Coppola, Noemi and Ruoppo, Elvira and Canfora, Federica and Mignogna, Gabriele and Mormile, Ilaria and Fiore, Antonia and Castaldo, Giuseppe and Mignogna, Michele Davide and Leuci, Stefania},
title = {CD4+ T Cells Predict Relapse in Pemphigus Vulgaris Treated With Rituximab: A Retrospective Study},
journal = {Oral Diseases},
year = {2026},
doi = {10.1111/odi.70234}
}
EUVIMED